MedTrace Logo

Optimising Mammography Screening Accuracy With Blood-based Biomarkers

NCT07049822 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 1200

Last updated 2026-03-09

No results posted yet for this study

Summary

The project aims to investigate whether breast cancer screening can be improved using blood tests, thereby reducing the number of unnecessary clinical mammographies. The Danish breast cancer screening program was implemented in 2007, and currently, all women aged 50-69 are invited every two years to participate. Those who have a suspecious screening mammography are referred to a clinical mammography where further assesment with more mammographies, ultra-sound and possibly biopsies are conducted. Around 75% of the women that are referred to further assesment can be classified as unnecessary, as no breastcancer is found. This results in avoidable and unpleasant procedures for individuals and strains healthcare resources.

The project seeks to reduce the number of these unnecessary clinical mammographies by investigating whether blood biomarkers can identify women at very low risk of breast cancer after a positive mammography screening. By utilizing blood tests, screening could become more personalized, precise, and resource-efficient for the healthcare system.

Conditions

Sponsors & Collaborators

  • Sygehus Lillebaelt

    collaborator OTHER

  • Vejle Hospital

    lead OTHER

Principal Investigators

  • Jonna S Madsen, Prof., MD · Sygehus Lillebaelt

  • Sisse H Njor, Professor · Sygehus Lillebaelt

Eligibility

Min Age
50 Years
Max Age
69 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-11-24
Primary Completion
2028-11-30
Completion
2029-12-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07049822 on ClinicalTrials.gov